Medical Oncology
About the Department
The department of Medical Oncology is one of the main pillars of this institute providing comprehensive cancer care for all types of solid tumors. The department caters maximum patients in terms of OPD services and daycare administration of chemotherapy in the hospital. Individual consultants have their focus on their respective field of interest thus providing latest cutting edge care and treatment to the patients. Apart from patient care, the Medical Oncology Department is famous for running several multicentric clinical trials, institutional work in the area of real-world data reviews and publications. The department has been running a NBE accredited DNB Medical Oncology (superspeciality) training program since’2019.
Consultants and fellows in the department regularly do academic activities and publish their research work in indexed journals. All the staff members including fellows have shown exemplary dedication to their profession and have functioned with all sincerity. As patients load in this institute increases day by day, the department is working towards expanding the service to minimize the waiting list of day care facilities and in-patients admission also.
-
OPD consultation- on an average the department caters around 200 patients per day in the OPD. This includes assessing patients for systemic chemotherapy, working up of new cases and their follow up. Screening for familial cancer syndromes are also being conducted in the department.
-
Day care and in-patient services: Most of the patients receive systemic therapy in the daycare. Inpatient services are available for management of chemotherapy related toxicities, supportive care and for few chemotherapy protocols which require continuous infusion.
-
Clinical Trials: – Medical Oncology department is proudly associated with numerous global Phase III clinical trials and investigator initiated clinical research where eligible patients are provided with the latest standard of therapy along with new investigational agents.. The current most clinical trials involve patients with lung, breast, gastrointestinal & urological cancers.
